THERAPY DOSSIER · th-d335c076c0ef

Recombinant human mesencephalic astrocyte-derived neurotrophic factor (MANF)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29883817 ↗2018Reported benefit

Mesencephalic Astrocyte-Derived Neurotrophic Factor Prevents Traumatic Brain Injury in Rats by Inhibiting Inflammatory Activation and Protecting the Blood-Brain Barrier.

RatTBIWeight-drop / impact-accelerationSprague-DawleyMaleHigh dose 20 micrograms in 20 microlitresAdministered after traumatic brain injury, with assessment 24 hours later

Model: Feeney free-falling weight-drop traumatic brain injury

High-dose recombinant human MANF increased the modified Garcia score and reduced brain water content and cerebral oedema volume, lowered blood-brain barrier permeability and reduced interleukin 1 beta and tumour necrosis factor alpha expression, with inhibition of P65 activation.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…